Thanks for the great question.
This is not directly brought up, but it's always an underlying concern that the costs of screening outweigh the benefits. We showed with a cost-effectiveness study that it would save over $400 million per year if we screened women, because we're shifting the cost away from treating breast cancer at advanced stages to being able to diagnose more women at early-stage breast cancer.
There's still a great deal of resistance about understanding this. We have to really emphasize that the costs we've estimated for cost-effectiveness underestimate the cost of advanced-stage breast cancers.